$9.09
1.20% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US6024961012
Symbol
MDXG
Sector
Industry

MiMedx Group, Inc. Stock price

$9.09
+3.24 55.38% 1M
+1.34 17.29% 6M
+0.32 3.65% YTD
+1.17 14.77% 1Y
+1.36 17.59% 3Y
+3.05 50.50% 5Y
-1.89 17.21% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.11 1.20%
ISIN
US6024961012
Symbol
MDXG
Sector
Industry

Key metrics

Market capitalization $1.34b
Enterprise Value $1.27b
P/E (TTM) P/E ratio 15.53
EV/FCF (TTM) EV/FCF 23.13
EV/Sales (TTM) EV/Sales 3.69
P/S ratio (TTM) P/S ratio 3.90
P/B ratio (TTM) P/B ratio 7.38
Revenue growth (TTM) Revenue growth 10.93%
Revenue (TTM) Revenue $342.81m
EBIT (operating result TTM) EBIT $63.65m
Free Cash Flow (TTM) Free Cash Flow $54.73m
Cash position $88.80m
EPS (TTM) EPS $0.59
P/E forward 30.50
P/S forward 3.87
EV/Sales forward 3.67
Short interest 3.40%
Show more

Is MiMedx Group, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

MiMedx Group, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a MiMedx Group, Inc. forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a MiMedx Group, Inc. forecast:

Buy
100%

Financial data from MiMedx Group, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
343 343
11% 11%
100%
- Direct Costs 58 58
3% 3%
17%
285 285
13% 13%
83%
- Selling and Administrative Expenses 207 207
1% 1%
60%
- Research and Development Expense 11 11
52% 52%
3%
67 67
245% 245%
19%
- Depreciation and Amortization 3.09 3.09
33% 33%
1%
EBIT (Operating Income) EBIT 64 64
331% 331%
19%
Net Profit 88 88
1,938% 1,938%
26%

In millions USD.

Don't miss a Thing! We will send you all news about MiMedx Group, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

MiMedx Group, Inc. Stock News

Neutral
GlobeNewsWire
12 days ago
Over 200 Unproven Skin Substitutes Will No Longer Be Covered Under Revised LCDs Company to Benefit from MACs' Commitment to Clinically Effective, Proven Products MARIETTA, Ga., Nov. 14, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today provided the following update on the Local Coverage Determinations (“LCDs”) regarding “Skin Substitute Grafts/Cellular...
Neutral
Seeking Alpha
26 days ago
MiMedx Group, Inc. (NASDAQ:MDXG ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Matt Notarianni - Head, Investor Relations Joe Capper - Chief Executive Officer Doug Rice - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Group Ross Osborn - Cantor Fitzgerald Brad Bowers - Mizuho Securities Carl Byrnes - Northland Capital...
Neutral
GlobeNewsWire
27 days ago
Net Sales of $84 million Grew 3% Year-Over-Year for the Third Quarter Third Quarter GAAP Net Income and Earnings Per Share were $8 Million and $0.05 , Respectively Third Quarter Adjusted EBITDA was $18 Million, or 22% of Net Sales Raises 2024 Net Sales Growth Expectations to the High Single-Digits Management to Host Conference Call Today, October 30, 2024, at 4:30 PM ET
More MiMedx Group, Inc. News

Company Profile

MiMedx Group, Inc. is an advanced wound care and an emerging therapeutic biologics company. It engages in developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The company processes the human placental tissue utilizing its proprietary PURION process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx Group was founded on July 30, 1985 and is headquartered in Marietta, GA.

Head office United States
CEO Joe Capper
Employees 895
Founded 1985
Website www.mimedx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today